TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17250775
Drug: Dexamphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine (10 mg)
Study: 14667790
Drug: Piperacillin-tazobactam 13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam 13.5 g divided Q6H
Study: 11007053
Drug: Moderate renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate renal failure, hypercalcaemia, low Bence-Jones protein excretion
Study: 28328759
Drug: Topical ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ropivacaine (1% ropivacaine)
Study: 22014897
Drug: Omitting elective
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omitting elective nodal irradiation (ENI) during thoracic irradiation with concurrent chemo-radiotherapy
Study: 15059505
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride (RLX) 60 mg/day for 12 months
Study: 9638964
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg (after dose increase)
Study: 9638964
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg (after dose increase)
Study: 2726115
Drug: Vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin E2 (3 mg)
Study: 25943662
Drug: IV with
Normalized name: AEROSOL POWDER, BREATH ACTIV WITH SENSOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV with oral glycerol (50% IV fluid, 50% oral fluid with added glycerol 1.5g/kg)
Study: 25943662
Drug: IV (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV (50% IV fluid, 50% oral fluid)
Study: 25943662
Drug: oral glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral glycerol (oral fluid with added glycerol 1.5g/kg)
Study: 25943662
Drug: oral (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral (oral fluid only)
Study: 25943662
Drug: IV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and IV with oral glycerol
Study: 25943662
Drug: IV with
Normalized name: AEROSOL POWDER, BREATH ACTIV WITH SENSOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV with oral glycerol
Study: 22553403
Drug: PEG (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG (500 mL ingested within 2 hours starting 30 minutes after swallowing the capsule)
Study: 22553403
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional preparation (control group A)
Study: 10696419
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg quinine salt/kg bodyweight daily for 7 days
Study: 10696419
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg quinine salt/kg bodyweight daily for 7 days
Study: 10696419
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg quinine salt/kg bodyweight daily for 7 days
Study: 2286000
Drug: Ceftriaxone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (3 or 4 g per day for 2 or 3 days)
Study: 26059981
Drug: rLH 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: rLH 150 IU/day administered at GnRH-ant administration
Study: 26059981
Drug: rLH 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: rLH 150 IU/day administered from the start of rFSH administration
Study: 26059981
Drug: rLH 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: rLH 75 IU/day administered at GnRH-ant administration
Study: 26059981
Drug: rLH 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: rLH 75 IU/day administered from the start of rFSH administration
Study: 26059981
Drug: rLH 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: rLH 150 IU/day administered at rFSH administration
Study: 26059981
Drug: rLH 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: rLH 75 IU/day administered at rFSH administration
Study: 24618336
Drug: Doxorubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (75 mg/m² by intravenous bolus on day 1 or 72 h continuous intravenous infusion)
Study: 24618336
Drug: Doxorubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin plus ifosfamide (Doxorubicin 75 mg/m²; 25 mg/m² per day, days 1-3 plus ifosfamide 10 g/m² over 4 days with mesna and pegfilgrastim)
Study: 22118808
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) or Escitalopram
Study: 17855198
Drug: Bilateral single-shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral single-shot paravertebral blocks (BSS-PVB) with low-dose fentanyl and 3 mL bupivacaine 0.5% each (T1-7)
Study: 17855198
Drug: High thoracic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High thoracic epidural analgesia (TEA) with bupivacaine 0.125% at 10 mL/hour
Study: 8331334
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NTR and PTI
Study: 31491384
Drug: Broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotics administered prior and subsequent to seasonal influenza vaccination
Study: 31491384
Drug: Broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotics administered to subjects with low pre-existing antibody titers
Study: 31491384
Drug: Broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotics treatment
Study: 23633090
Drug: Treatment-as-usual plus
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual plus take-home emergency naloxone
Study: 22435280
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg single IV bolus (Precalculated group, PG)
Study: 22435280
Drug: Titration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration of Propofol (Titration group, TG)
Study: 15606472
Drug: Dorzolamide/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/timolol fixed combination (D/T)
Study: 11528357
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg norethindrone acetate (NA)/5 microg ethinyl estradiol (EE)
Study: 11528357
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg norethindrone acetate (NA)/5 microg ethinyl estradiol (EE)
Study: 11528357
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg norethindrone acetate (NA)/10 microg ethinyl estradiol (EE)
Study: 11528357
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogens (CEE)/2.5 mg medroxyprogesterone acetate (MPA)
Study: 7705552
Drug: sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 2 g b.d.
Study: 3300310
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of norfloxacin (600 mg twice daily)
Study: 3300310
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of norfloxacin (800 mg)
Study: 3300310
Drug: Single-dose ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ampicillin (3.5 g)/probenecid (1.0 g)
Study: 1062553
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B toothbrush
Study: 30047786
Drug: Escitalopram (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10‐20 mg)
Study: 21716274
Drug: Clopidogrel regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel regimen of 300 mg loading dose (LD) and 75 mg/day maintenance dose (MD) for 4 days
Study: 21716274
Drug: Clopidogrel regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel regimen of 600 mg LD and 150 mg/day MD
Study: 21716274
Drug: Clopidogrel regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel regimen of 75 mg/day MD
Study: 21716274
Drug: Clopidogrel regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel regimen of 150 mg/day MD
Study: 19648146
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 220 mg and 150 mg
Study: 16729745
Drug: Continuous low-volume
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous low-volume infusion (10 cc of dye infused over 2.5 hours)
Study: 16729745
Drug: Intermittent high-volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-volume bolus infusion (10 cc bolus of dye)
Study: 9243208
Drug: Cyclic conjugated
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic conjugated oestrogens 0.3 mg/day
Study: 9243208
Drug: Cyclic conjugated
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic conjugated oestrogens 0.625 mg/day
Study: 9243208
Drug: Cyclic conjugated
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic conjugated oestrogens 1.25 mg/day
Study: 30403495
Drug: Webdia app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Webdia app intervention for 3 months with monthly feedback and adaptation of treatment
Study: 18317243
Drug: Triflusal (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (900 mg for 18 months)
Study: 16215013
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zinc/d in cherry syrup
Study: 16215013
Drug: Cherry syrup
Normalized name: CHERRY SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cherry syrup alone (placebo)
Study: 10215647
Drug: MK‐966 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐966 (50 mg every day)
Study: 1706607
Drug: HIV-1 recombinant
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 recombinant gp160 vaccine (40 or 80 micrograms)
Study: 1706607
Drug: HIV-1 recombinant
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 recombinant gp160 vaccine (fourth immunization)
Study: 1706607
Drug: HIV-1 recombinant
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 recombinant gp160 vaccine
Study: 30064953
Drug: ACCU-CHEK Inform
Normalized name: Accu-Chek Inform II System Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACCU-CHEK Inform II displaying '32 mg/dL' reading
Study: 27194176
Drug: FOLFOX (fluorouracil-oxaliplatin-folinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX (fluorouracil-oxaliplatin-folinic acid) combined with concurrent radiotherapy (41.4 Grays)
Study: 27194176
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and paclitaxel combined with concurrent radiotherapy (41.4 Grays)
Study: 24227768
Drug: Buprenorphine (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (32 mg/day i.m.)
Study: 24227768
Drug: Morphine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (120 mg/day i.m.)
Study: 22831286
Drug: Fruit and
Normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit and vegetable puree-based drinks (FVPD) 200 mL daily for 6 weeks
Study: 12174518
Drug: Antiplatelet drug
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet drug triflusal (600 mg)
Study: 12174518
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with anticoagulation (mean INR of 1.85)
Study: 12174518
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with anticoagulation (mean INR of 2.15)
Study: 7793997
Drug: AO-90 (500-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: AO-90 (500-750 ml/day)
Study: 7793997
Drug: Commercial amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial amino acid solution (600-800 ml/day)
Study: 393386
Drug: DTIC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC at a dose of 200 mg/m2 iv on Days 1‐5 and cis‐dichlorodiammine‐platinum(II) at a dose of 40 mg/m2 iv on Days 1 and 4, repeated every 4 weeks (group A)
Study: 393386
Drug: DTIC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC at a dose of 200 mg/m2 iv on Days 1‐5 and cis‐dichlorodiammine‐platinum(II) at a dose of 40 mg/m2 iv on Days 1 and 4, repeated every 4 weeks, plus procarbazine at a dose of 75 mg/m2 orally daily on Days 1‐8 and vincristine at a dose of 1.4 mg/m2 iv on Day 1 (group B)
Study: 30060681
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (CSI) alone
Study: 30060681
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (CSI) with 3 weeks of immobilization
Study: 31262544
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hydrocortisone orally
Study: 25694068
Drug: Milled flaxseed
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milled flaxseed (30 g/day)
Study: 25694068
Drug: Milled flaxseed
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milled flaxseed (30 g/day) + cholesterol-lowering medications (CLM)
Study: 25694068
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 g whole wheat) + cholesterol-lowering medications (CLM)
Study: 21689900
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 μg
Study: 18925978
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) B12 replacement therapy
Study: 18925978
Drug: Normal serum
Normalized name: Albumin, Normal Serum, Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal serum B12 levels (>300 pg/mL)
Study: 9523927
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (2 mg, 4 mL)
Study: 9523927
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 mL of nebulized normal saline)
Study: 2039811
Drug: 49.2 mg
Normalized name: fusidate 49.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 49.2 mg pseudoephedrine (ACTIFED)
Study: 2039811
Drug: 1.51 L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.51 L mineral water
Study: 30663520
Drug: Subanaesthetic intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanaesthetic intravenous ketamine infusion
Study: 29273594
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 0.8 mg combined with enalapril 10 mg
Study: 26590016
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of normal saline injected into the knee joint of the experimental group.
Study: 22898278
Drug: Specific sublingual
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific sublingual immunotherapy with dermatophagoides farinae drops
Study: 22898278
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment alone (Control)
Study: 20724562
Drug: L-arginine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (6 g in 500 ml beverage)
Study: 18424200
Drug: 6% Hydroxyethylstarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% Hydroxyethylstarch 130/0.4 (median of 750 ml administered)
Study: 12540643
Drug: Nimodipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (60 mg orally every 4 hours)
Study: 12540643
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (intravenous according to institutional protocol)
Study: 10653212
Drug: biperiden (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: biperiden (4 mg)
Study: 10653212
Drug: trihexyphenidyl (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: trihexyphenidyl (5 mg)
Study: 8447161
Drug: Cold-adapted live
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted live attenuated vaccine (two doses)
Study: 8447161
Drug: Whole-virus inactivated
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virus inactivated vaccine (one dose)
Study: 31268610
Drug: Alteplase 2
Normalized name: alteplase 20 mg INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 2 mg
Study: 31268610
Drug: Alteplase 1
Normalized name: alteplase 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 1 mg
Study: 26833336
Drug: Ad26.EnvA and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.EnvA and Ad35.Env (both administered at a dose of 5 × 10^10 viral particles)
Study: 24743802
Drug: Alprazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.25 mg)
Study: 20975066
Drug: Sequential high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential high-dose chemotherapy (SHDCT) before myeloablative therapy
Study: 20975066
Drug: Standard arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard arm (A) with myeloablative therapy with carmustine, BEAM followed by PBSCT
Study: 18925347
Drug: Treatment-naive group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-naive group
Study: 18925347
Drug: One to
Normalized name: One Touch
Approvals — FDA: no, EMA: no, PMDA: no
Description: One to two prior treatments group
Study: 18925347
Drug: Three or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three or more prior treatments group
Study: 15847747
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 0.2 mg daily for 3 months
Study: 15847747
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5.2 mg daily for 3 months
Study: 12059949
Drug: Ritonavir/Indinavir at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir/Indinavir at 400/400 mg BID in combination with two NRTIs (ZDV/3TC, d4T/3TC, or d4T/ddI)
Study: 12059949
Drug: Ritonavir/Indinavir at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir/Indinavir at 400/400 mg BID in combination with two NRTIs
Study: 1756263
Drug: Postoperative locoregional
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative locoregional and pelvic radiotherapy (RX) and Poly(A).Poly(U) (AU), 60 mg IV once a week for 6 weeks
Study: 1756263
Drug: CMF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (cyclophosphamide 100 mg/sqm P.O. on days 1‐14, methotrexate 40 mg/sqm IV on day 1 and 8, fluorouracil 600 mg/sqm IV on day 1 and 8; monthly cycle, for 6 months)
Study: 6802412
Drug: Three-day course
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day course of amoxycillin (25 mg/kg daily)
Study: 6802412
Drug: Ten-day course
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten-day course of amoxycillin (25 mg/kg daily)
Study: 17537209
Drug: Defibrillator implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrillator implant
Study: 15530197
Drug: Nursing session
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing session with five symposia and short oral presentations.
Study: 11474345
Drug: C (5
Normalized name: ferric (59Fe) citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (5 mg x kg(‐1))
Study: 11474345
Drug: E (1
Normalized name: methionine (11C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E (1 mg x kg(‐1))
Study: 10921014
Drug: Intraperitoneal perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal perfusion chemotherapy (IPPC) with 1 g 5-Fu and 10 mg MMC in warm sterile water, once per day for 6 days.
Study: 10921014
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 1 g 5-Fu and 8 mg MMC, once per day for 6 days (Control group).
Study: 7977595
Drug: Povidone-iodine 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine 2.5% ophthalmic solution
Study: 7977595
Drug: Silver nitrate
Normalized name: Silver Nitrate
DrugBank: Silver (DB12965)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silver nitrate 1% ophthalmic solution
Study: 7977595
Drug: Erythromycin 0.5%
Normalized name: ERYTHROMYCIN 0.5% OINT,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 0.5% ointment
Study: 2596940
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg/d) plus potassium supplement (20 mmol/d)
Study: 2596940
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg/d) plus potassium supplement (40 mmol/d)
Study: 2596940
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg/d) with triamterene (75 mg/d)
Study: 31345163
Drug: Curcumin 1500
Normalized name: Nature's Truth Turmeric Curcumin 1500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 1500 mg
Study: 24453924
Drug: Sulphurous thermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphurous thermal water inhalation
Study: 21960699
Drug: Nebulized levalbuterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized levalbuterol 0.63 mg
Study: 19120892
Drug: rabeprazole, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole, amoxicillin, and GAT for 7 days (RAG)
Study: 19120892
Drug: rabeprazole and
Normalized name: Dexrabeprazole and domperidone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole and amoxicillin (RA)